最先端の技術と優れた美容解決策を
提供することに全力を注ぎます。
Cross-linking Technology
Long-chain HA molecules are retained and crosslinked by self-recognition and then chemically crosslinked. At the same time, free BDDE and suspended cross-linking BDDE are removed by double washing technology, minimizing the BDDE content and reducing the side effects of the technology.
Dermal injection of cross-linked hyaluronic acid improves skin texture mainly through the following aspects:
① Directly replenishing hyaluronic acid (HA) in the skin to enhance hydration and increase skin volume;
② Promoting the proliferation of keratin-forming cells, resulting in an increase in the density of epidermal protrusions, an increase in the area of the dermal-epidermal junction (DEJ), and thickening of the epidermis;
③ Promote the mechanical pull of collagen fibers on fibroblasts by altering intradermal tension, leading to fibroblast proliferation, upregulate the expression of the TGF-β/Smad/CTGF axis, and increase the expression of the matrix metalloproteinase inhibitor, TIMP, thus promoting the synthesis of collagen and other ECM proteins and inhibiting their breakdown;
④ Up-regulate the expression of VEGF, promote the proliferation of vascular endothelial cells, which is favorable to dermal vascular neogenesis and increase the blood supply and nutrition of the skin.
*TGF-β: Transforming Growth Factor-β
Smad: SMADs are intracellular regulatory proteins that can be subclassified as either receptor-regulated SMADs (R-SMAD), common-mediator SMADs (Co-), or inhibitor SMADs. SMADs), common-mediator SMADs (Co- SMADs), or inhibitory SMADs (I-SMADs).
CTGF:Connective tissue growth factor
VEGF:Vascular endothelial growth factor
Revolutionizing Skincare:
Benefits
of Refinex® Monophasic-Crosslinking
In the ever-evolving world of skincare technology, Refinex® Monophasic-Crosslinking stands out as a groundbreaking innovation. This advanced technique enhances the effectiveness and safety of dermal fillers, providing superior results with minimal side effects.
Refinex® Monophasic-Crosslinking utilizes a sophisticated approach to improve the stability and performance of Hyaluronic Acid (HA) used in dermal fillers. This technique involves two key processes:
Long-chain HA Retention and Crosslinking:
The technology first ensures that long-chain HA molecules are retained and crosslinked through a process of self-recognition. These molecules are then chemically crosslinked to form a stable network.
Purification with Double Washing Technology:
Free BDDE (Butanediol Diglycidyl Ether) and suspended cross-linking BDDE are removed using a double washing process. This step significantly reduces the BDDE content, minimizing potential side effects and ensuring a safer product for the user.
The crosslinking process provides strong fixation, ensuring that the dermal filler remains in place and does not migrate from the treatment area. This stability is crucial for achieving precise and natural-looking results.
The high adhesion properties of the product ensure excellent support and integration with the skin. This means that the filler not only stays where it is applied but also enhances the overall texture and contour of the treated area.
The increased cross-linking density results in a denser network of HA molecules, which contributes to less edema (swelling) after the procedure. Patients can expect a smoother recovery and minimal post-treatment swelling.
Refinex® Monophasic-Crosslinking represents a significant advancement in dermal filler technology. Its ability to retain and stabilize long-chain HA molecules while minimizing BDDE content makes it a preferred choice for those seeking both efficacy and safety in their skincare treatments. The result is a dermal filler that offers strong fixation, high support, and reduced post-treatment swelling, providing a superior experience and outcome for users.
*For more information on how Refinex® Monophasic-Crosslinking can benefit you, consult with a skincare professional to explore your options.
